1. We studied the acute haemodynamic effects of cromakalim, a vasodilator which activates smooth muscle potassium channels, in 11 patients with ischaemic heart disease undergoing routine cardiac catheterisation. A similar group of six patients given placebo were studied under identical conditions. 2. There were no significant differences in baseline haemodynamic parameters between the two groups. 3. Following intravenous cromakalim (15 micrograms kg-1) cardiac output increased by 30% (P less than 0.05 vs placebo) while systolic arterial pressure decreased by 8% (P less than 0.05), systemic vascular resistance decreased by 29% (P less than 0.01) and pulmonary vascular resistance decreased by 24% (P less than 0.01) at plasma concentrations of the (+)- and (-)-enantiomers of cromakalim of 6.2 +/- 0.5 ng ml-1 and 10.0 +/- 1.0 ng ml-1 respectively. 4. There were no significant differences in diastolic arterial pressure, left ventricular dP/dt and stroke volume between the two groups. Heart rate increased by 11% following cromakalim but this did not achieve significance. 5. These findings confirm that cromakalim acts primarily as an arteriolar vasodilator producing an improvement in cardiac performance. Cromakalim may be of benefit in the treatment of patients with ischaemic heart disease.
展开▼
机译：1.我们研究了克罗马卡林（一种激活血管平滑肌钾通道的血管扩张药）对11名接受常规心脏导管插入术的缺血性心脏病患者的急性血液动力学作用。在相同条件下研究了一组相似的六名接受安慰剂的患者。 2.两组之间的基线血流动力学参数无显着差异。 3.静脉注射克罗马卡林（15微克kg-1）后，心排血量增加30％（与安慰剂相比，P小于0.05），而收缩压下降8％（P小于0.05），全身血管阻力下降29％（P血浆浓度为6.2 +/- 0.5 ng ml-1和10.0 +/-的cromakalim（+）-和（-）-对映体的血浆浓度时，肺血管阻力降低了24％（P小于0.01）。分别为1.0 ng ml-1。 4.两组之间舒张期动脉压，左心室dP / dt和中风量无显着差异。克罗卡林治疗后，心率增加了11％，但这并未达到显着水平。 5.这些发现证实了克罗马卡林主要起小动脉血管扩张剂的作用，从而改善了心脏的机能。克romakalim可能对缺血性心脏病患者的治疗有益。
展开▼
